July 6 (Reuters) - GENSIGHT BIOLOGICS SA:

* GENSIGHT BIOLOGICS REPORTS SUSTAINED EFFICACY AND SAFETY AMONG LHON PATIENTS THREE YEARS AFTER LUMEVOQ® TREATMENT

* NEW DATA WILL REINFORCE SUBMISSION OF LUMEVOQ® FOR MARKETING AUTHORIZATION IN EUROPEAN UNION, WHICH IT INTENDS TO FILE IN SEPTEMBER 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

Source: Reuters

Powered by NewsAPI.org